BLUE - ブル―バ―ド・バイオ （bluebird bio Inc.） ブル―バ―ド・バイオBLUEのチャート
BLUEの企業情報
| symbol | BLUE |
|---|---|
| 会社名 | bluebird bio Inc （ブル―バ―ド・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ブルーバード(bluebird bio Inc.)は臨床開発段階にあるバイオテクノロジー企業であり、重症及び癌の遺伝子治療の開発に集中する。同社はレンチウイルスに基づく遺伝子治療と遺伝子編集機能を通じて、これらの分野におけるさまざまなアプリケーションを備えた統合製品プラットフォームを作成した。同社の複数の遺伝病に対する遺伝子臨床プログラムは輸血依存性β-サラセミアと重症鎌状赤血球病（SCD）を治療するLentiGlobin製品候補、脳性副腎白質ジストロフィー（CALD）を治療するLenti-D製品候補を含む。同社の腫瘍学におけるプログラムはキメラ抗原受容体（CAR） T細胞受容体（TCR）療法を含むT細胞ベースの免疫療法の開発に集中する。同社の腫瘍のリード製品候補bb2121は多発性骨髄腫の治療のためのCAR T細胞産物候補である。同社はパイプラインに応用する可能のメガTAL /ホーミングエンドヌクレアーゼ遺伝子編集技術を利用する発見研究プログラムがある。 ブル―バ―ド・バイオは、米国のバイオ医薬品企業。遺伝性疾患や難病向けに遺伝子治療製品の開発を手掛ける。主要製品候補はレンチDと呼ばれる副腎白質ジストロフィ―の治療薬と、サラセミアおよび鎌状赤血球病治療薬のレンチグロビンである。また、がん治療分野にて、がん細胞を破壊し患者自身のT細胞の遺伝子組換えなどの研究開発を手掛ける。 we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day. |
| 本社所在地 | 60 Binney Street Cambridge MA 02142 USA |
| 代表者氏名 | Daniel S. Lynch ダニエルS.リンチ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 339-499-9300 |
| 設立年月日 | 33695 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 479人 |
| url | www.bluebirdbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/blue |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -444.21700 |
| 終値（lastsale） | 133.44 |
| 時価総額（marketcap） | 7226832311.04 |
| 時価総額 | 時価総額（百万ドル） 7380.099 |
| 売上高 | 売上高（百万ドル） 35.68700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6458.457 |
| 当期純利益 | 当期純利益（百万ドル） -351.15500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 bluebird bio Inc revenues increased 1% to $23.8M. Net loss increased 87% to $261.1M. Revenues reflect Collaboration revenue increase of 78% to $23M. Higher net loss reflects Change in fair value of contingent consi increase of 72% to $796K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.41 to -$5.22. |
BLUEのテクニカル分析
BLUEのニュース
Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial 2023/06/02 14:15:00 Accesswire
AUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is working with world-class institutions in developing new drugs from the company''s pipeline of gene therapy candidates in order to provide novel treatment approaches. Its oncology program utilizes its proprietary non-viral ONCOPREX® Nanoparticle Delivery System, which Genprex believes is the first systemic gene therapy delivery platform used for cancer in humans. The company''s lead drug candidate is called REQORSA®. The immunogene therapy (also known as quaratusugene ozeplasmid) is for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and uses the company''s unique, proprietary ONCOPREX® Nanoparticle Delivery System. The drug may be helpful for treating patients who have already demonstrated drug resistance to other treatments.
Friday’s Top Analyst Upgrades and Downgrades: Chevron, Chewy, CSX, C3.ai, Exxon, Macy’s, Micron Technology, Target and More 2023/06/02 12:52:42 24/7 Wall street
Friday''s top analyst upgrades and downgrades included Aramark, Bluebird Bio, Chevron, Chewy, CSX, C3.ai, Equitrans Midstream, Exxon Mobil, Macy’s, Micron Technology, Okta, Phillips 66 and Target.
Barclays Upgrades bluebird bio to Overweight 2023/06/01 08:03:01 Investing.com
https://www.investing.com/news/pro/barclays-upgrades-bluebird-bio-to-overweight-432SI-3095849
Regenerative Medicine Market Report Size, Research Analysis, Share, Industry Growth, Opportunities, Business Expansion, Forecast to 2027 2023/05/10 13:00:00 SBWire
In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function. Northbrook, IL 60062 -- ( SBWIRE ) -- 05/10/2023 -- The Global Regenerative Medicine Market in terms of revenue was estimated to be worth $12.2 Billion in 2022 and is poised to grow at a CAGR of 27.2% from 2022 to 2027. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and issues associated with commercialization and regulatory compliance factors are expected to restrain the market growth during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579 Regenerative Medicine Industry Dynamics Drivers: Availability of funding and rising investments in R&D The rising need for improved therapies for cancer, diabetes, skin diseases, musculoskeletal diseases, chronic wounds, burns, and CVD has resulted in increased research activities.
bluebird bio files for $350M mixed shelf offering 2023/05/09 21:37:52 Seeking Alpha
bluebird bio (BLUE) has filed for a $350M mixed shelf securities offering. Read more here.
bluebird bio Sells Second Priority Review Voucher for $95 Million 2023/01/06 12:30:00 Wallstreet:Online
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million. bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA) approvals of ZYNTEGLO (betibeglogene autotemcel) for the treatment of beta-thalassemia
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023/01/05 13:00:00 Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the
bluebird bio Inc.’s Stock Price Relatively Up Recently, But Trouble Is Still Brewing 2023/01/03 15:00:00 Stocks Register
bluebird bio Inc. (NASDAQ:BLUE) traded at $6.92 at close of the session on Friday, 12/30/22, made an upward move of 0.58% on its previous day’s price. Looking at the stock we see that its previous close was $6.88 and the beta (5Y monthly) reads 1.00 with the day’s price range being $6.67 – $6.93. In … bluebird bio Inc.’s Stock Price Relatively Up Recently, But Trouble Is Still Brewing Read More »
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer 2023/01/03 13:00:00 Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings mor
Bluebird bio completes sale of priority review voucher to argenx (NASDAQ:BLUE) 2022/12/30 10:48:11 Seeking Alpha
bluebird bio (BLUE) has closed the sale of a rare pediatric disease priority review voucher ((PRV)) to Dutch biotech argenx SE (ARGX) for $102M in cash. Read the full story here.
Roadblocks To A Successful stocks: bluebird bio, Inc. (NASDAQ:BLUE 22.05%), Virgin Galactic Holdings, Inc. (NYSE:SPCE -17.46%) 2022/08/07 23:40:43 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Roadblocks To A Successful stocks: bluebird bio, Inc. (NASDAQ:BLUE 22.05%), Virgin Galactic Holdings, Inc. (NYSE:SPCE -17.46%) appeared first on Stocks Equity .
BLUE stock gains as earnings update draws upgrade at Barclays (NASDAQ:BLUE) 2022/08/05 15:10:48 Seeking Alpha
The shares of bluebird bio rose in the morning hours Friday after Barclays upgraded the gene therapy developer to Equal Weight from Underweight following the company’s 2Q 2022…
Barclays Upgrades bluebird bio to Equalweight 2022/08/05 15:03:02 Investing.com
https://www.investing.com/news/pro/barclays-upgrades-bluebird-bio-to-equalweight-432SI-2865504